Background: In the past, elevated estradiol levels were reported to downregulate the iron regulatory hormone hepcidin, thereby potentially improving iron metabolism. As estrogen plays a role in regulating the menstrual cycle and can influence the cytokine interleukin-6 (IL-6; a hepcidin up-regulator), this investigation examined the effects of estradiol supplementation achieved by the use of a monophasic oral contraceptive pill (OCP) on IL-6, hepcidin levels and iron status during the hormone-deplete versus hormone-replete phases within an oral contraceptive cycle (OCC). Methods: Fifteen healthy female OCP users were recruited and provided a venous blood sample on 2 separate mornings during a 28-day period. These included (a) days 2-4 of the OCC, representing a hormone-free withdrawal period (WD); (b) days 12-14 of the OCC, representing the end of the first week of active hormone therapy (AHT). Results: IL-6 and hepcidin levels were not significantly different at WD and AHT. Serum ferritin was significantly higher (p = 0.039) during AHT as compared to WD. Conclusions: Fluctuations in OCP hormones (estradiol and/or progestogen) had no effect on basal IL-6 and hepcidin levels in young women. Nevertheless, elevated ferritin levels recorded during AHT may indicate that OCP hormones can positively influence iron stores within an OCC despite unchanged hepcidin levels.

Keywords:
Progesterone, Iron metabolism, Menstrual cycle, Iron deficiency, Estrogen
1.
McClung J, Karl JP, Cable SJ, Williams KW, Nindl BC, Young AJ, Lieberman HR: Randomized, double-blind, placebo-controlled trial of iron supplementation in female soldiers during military training: effects on iron status, physical performance, and mood. Am J Clin Nutr 2009;90:124-131.
2.
Harvey LJ, Armah CN, Dainty JR, Foxall RJ, John Lewis D, Langford NJ, Fairweather-Tait SJ: Impact of menstrual blood loss and diet on iron deficiency among women in the UK. Br J Nutr 2005;94:557-564.
3.
Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461-2463.
4.
Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 2004;113:1271-1276.
5.
Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
6.
Robertson LS, Iwanowicz LR, Marranca JM: Identification of centrarchid hepcidins and evidence that 17β-estradiol disrupts constitutive expression of hepcidin-1 and inducible expression of hepcidin-2 in largemouth bass (Micropterus salmoides). Fish Shellfish Immuno 2009;26:898-907.
7.
Yang Q, Jian J, Katz S, Abramson SB, Huang X: 17β-estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. Endocrinology 2012;153:3170-3178.
8.
Lehtihet M, Bonde Y, Beckman L, Berinder K, Hoybye C, Rudling M, Sloan JH, Konrad RJ, Angelin B: Circulating hepcidin-25 is reduced by endogenous estrogen in humans. PLoS One 2016;11:e0148802.
9.
Pottratz S, Bellido T, Mocharla H, Crabb D, Manolagas SC: 17β-estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptor-dependent mechanism. J Clin Invest 1994;93:944-950.
10.
Sugita-Konishi Y, Shimura S, Nishikawa T, Sunaga F, Naito H, Suzuki Y: Effect of Bisphenol A on non-specific immunodefenses against non-pathogenic Escherichia coli. Toxicol Lett 2003;136:217-227.
11.
Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D: Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005;106:1864-1866.
12.
Sim M, Dawson B, Landers G, Trinder D, Peeling P: Iron regulation in athletes: exploring the menstrual cycle and effects of different exercise modalities on hepcidin production. Int J Sport Nutr Exerc Metab 2014;24:177-187.
13.
The Royal College of Pathologists Australasia: Iron Studies Standardised Reporting Protocol. Surry Hills, RCPA, 2013.
14.
Ives SJ, Blegen M, Coughlin MA, Redmond J, Matthews T, Paolone V: Salivary estradiol, interleukin-6 production, and the relationship to substrate metabolism during exercise in females. Eur J Appl Physiol 2011;111:1649-1658.
15.
Kroot JCC, Laarakkers CM, Geurts-Moespot AJ, Grebenchtchikov N, Pickkers P, van Ede AE, Peters HP, van Dongen-Lases E, Wetzels JF, Sweep FC, Tjalsma H, Swinkels DW: Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 2010;56:1570-1579.
16.
Galesloot TE, Vermeulen SH, Geurts-Moespot AJ, Klaver SM, Kroot JJ, van Tienoven D, Wetzels JF, Kiemeney LA, Sweep FC, den Heijer M, Swinkels DW: Serum hepcidin: reference ranges and biochemical correlates in the general population. Blood 2011;117:e218-e225.
17.
Rishi G, Wallace DF, Subramaniam VN: Hepcidin: regulation of the master iron regulator. Biosci Rep 2015;35:pii:e00192.
18.
Angstwurm MW, Gärtner R, Ziegler-Heitbrock HW: Cyclic plasma IL-6 levels during normal menstrual cycle. Cytokine 1997;9:370-374.
19.
Jilma B, Dirnberger E, Löscher I, Rumplmayr A, Hildebrandt J, Eichler HG, Kapiotis S, Wagner OF: Menstrual cycle-associated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-reactive protein. J Lab Clin Med 1997;130:69-75.
20.
Salkeld BD, MacAulay JC, Ball RW, Cannon JG: Modulation of body temperature, interleukin-6 and leptin by oral contraceptive use. Neuroimmunomodulation 2001;9:319-325.
21.
Konecna L, Yan MS, Miller LE, Scholmerich J, Falk W, Straub RH: Modulation of IL-6 production during the menstrual cycle in vivo and in vitro. Brain Behav Immun 2000;14:49-61.
22.
Milman N, Kirchhoff M, Jørgensen T: Iron status markers, serum ferritin and hemoglobin in 1359 Danish women in relation to menstruation, hormonal contraception, parity, and postmenopausal hormone treatment. Ann Hematol 1992;65:96-102.
23.
Frassinelli-Gunderson EP, Margen S, Brown JR: Iron stores in users of oral contraceptive agents. Am J Clin Nutr 1985;41:703-712.
24.
Larsson G, Milsom I, Lindstedt G, Rybo G: The influence of a low-dose combined oral contraceptive on menstrual blood loss and iron status. Contraception 1992;46:327-334.
25.
Kim I, Yetley EA, Calvo MS: Variations in iron-status measures during the menstrual cycle. Am J Clin Nutr 1993;58:705-709.
26.
Peeling P, Sim M, Badenhorst CE, Dawson B, Govus AD, Abbiss CR, Swinkels DW, Trinder D: Iron status and the acute post-exercise hepcidin response in athletes. PLoS One 2014;9:e93002.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.